{"id":6444,"date":"2017-11-03T12:03:00","date_gmt":"2017-11-03T12:03:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=6444"},"modified":"2021-12-01T08:47:44","modified_gmt":"2021-12-01T08:47:44","slug":"pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/","title":{"rendered":"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<ul class=\"wp-block-list\"><li><a href=\"https:\/\/www.semanticscholar.org\/author\/Helena-Rolandsdotter\/9835201\">Helena Rolandsdotter<\/a> Published&nbsp;2017 Medicine<\/li><\/ul>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Finally, we studied the immunological profile in blood at onset and in intestinal mucosa at onset and after GMA and EEN treatment. We conclude that an active approach is needed in the care of children with IBD to achieve and maintain remission. Our findings reveal that the children on IFX maintenance treatment were only in remission in 28% of the visits. The combination of GMA and mesalazine was found to be a safe and effective treatment in children with newly onset IBD. It seems plausible to speculate that the decreases in mucosal cytokines after the induction of remission may explain the good clinical result. Moreover, a change in the mucosal cytokine profile after induction of remission with EEN was observed. By investigating the chemokine receptors, we found a possible prognostic IBD marker, and by analyzing the cytokine profiles in mucosal biopsies, we have extended the knowledge of immunological phenotypes in children with IBD. Suggestions for the future Corticosteroid-free treatment alternatives must be explored and those currently in use must be optimized. To conclude, more and bigger studies are needed to explore the pathogenesis of IBD to determine new treatment alternatives.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.semanticscholar.org\/paper\/Pediatric-inflammatory-bowel-disease-%3A-clinical-and-Rolandsdotter\/e3d901c2c80db622f6cfbf92b03ee403b6e4a9b6#paper-header\">https:\/\/www.semanticscholar.org\/paper\/Pediatric-inflammatory-bowel-disease-%3A-clinical-and-Rolandsdotter\/e3d901c2c80db622f6cfbf92b03ee403b6e4a9b6#paper-header<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Helena Rolandsdotter Published&nbsp;2017 Medicine Finally, we studied the immunological profile in blood at onset and in intestinal mucosa at onset and after GMA and EEN treatment. We conclude that an active approach is needed in the care of children with IBD to achieve and maintain remission. Our findings reveal that the children on IFX maintenance [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[147,312,374,405,313],"class_list":["post-6444","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-immunology","scientific_tags-inflammatory-bowel-disease","scientific_tags-pediatric","scientific_tags-pediatry"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Helena Rolandsdotter Published&nbsp;2017 Medicine Finally, we studied the immunological profile in blood at onset and in intestinal mucosa at onset and after GMA and EEN treatment. We conclude that an active approach is needed in the care of children with IBD to achieve and maintain remission. Our findings reveal that the children on IFX maintenance [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-01T08:47:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/\",\"name\":\"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2017-11-03T12:03:00+00:00\",\"dateModified\":\"2021-12-01T08:47:44+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/","og_locale":"fr_FR","og_type":"article","og_title":"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte","og_description":"Helena Rolandsdotter Published&nbsp;2017 Medicine Finally, we studied the immunological profile in blood at onset and in intestinal mucosa at onset and after GMA and EEN treatment. We conclude that an active approach is needed in the care of children with IBD to achieve and maintain remission. Our findings reveal that the children on IFX maintenance [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/","og_site_name":"Adacyte","article_modified_time":"2021-12-01T08:47:44+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/","name":"Pediatric inflammatory bowel disease : clinical and immunological aspects on remission treatment - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2017-11-03T12:03:00+00:00","dateModified":"2021-12-01T08:47:44+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/pediatric-inflammatory-bowel-disease-clinical-and-immunological-aspects-on-remission-treatment\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/6444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=6444"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=6444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}